Cancer drugs approved quickly but not to patient's benefit: York University researcher
Dr. Joel Lexchin cites earlier research reviewing solid cancer drugs within 10 years of EMA approval to point out that these drugs improved survival by just over a month
2015-05-07
(Press-News.org) TORONTO, May 7, 2015 -- Highly priced cancer drugs get rushed approvals despite poor trial methodology and little effect on the longevity of patients, cautions York University Professor Dr. Joel Lexchin in the School of Health Policy and Management.
"Patients and their doctors should demand that regulators require pharma companies to provide clear evidence of clinical effectiveness of the drugs, resulting from rigorous methodology," suggests Lexchin. "Drug agencies like the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) don't actually look at whether people live longer."
In an article in the British Medical Journal, titled "Why do cancer drugs get such an easy ride?", Lexchiin and co-author Donald Light, a professor in the School of Osteopathic Medicine, Rowan University in New Jersey, note that accelerated approval and shortened review times also make it a smooth sail for cancer drugs.
Lexchin cites earlier research reviewing solid cancer drugs within 10 years of EMA approval to point out that these drugs improved survival by just over a month.
"Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression-free and overall survival of only 2.5 and 2.1 months, respectively," he says adding, "Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients."
INFORMATION:
The authors observe that pharma companies are having an easy ride with the European and US regulators, who are allowing them to test cancer drugs using surrogate measures instead of survival and other patient-centred measures.
York University is helping to shape the global thinkers and thinking that will define tomorrow. York U's unwavering commitment to excellence reflects a rich diversity of perspectives and a strong sense of social responsibility that sets us apart. A York U degree empowers graduates to thrive in the world and achieve their life goals through a rigorous academic foundation balanced by real-world experiential education. As a globally recognized research centre. York U is fully engaged in the critical discussions that lead to innovative solutions to the most pressing local and global social challenges. York U's 11 faculties and 25 research centres are thinking bigger, broader and more globally, partnering with 280 leading universities worldwide. York U's community is strong: 55,000 students, 7,000 faculty and staff, and more than 275,000 alumni.
ELSE PRESS RELEASES FROM THIS DATE:
2015-05-07
Compliance with post-treatment surveillance, income level and the travel distance for follow-up care had effects on survival in patients with head and neck squamous cell cancer (HNSCC), according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.
Post-treatment surveillance is a key component for patients with HNSCC, a cancer with a five-year survival rate of only slightly above 50 percent. The National Comprehensive Cancer Network guidelines recommend follow-up should consist of visits at least every one to three months during the first year after ...
2015-05-07
The use of cholesterol-lowering statins when men initiated androgen deprivation therapy for prostate cancer was associated with longer time to progression of the disease, according to an article published online by JAMA Oncology.
The gene SLCO2B1 acts as a transporter that enables a variety of drugs and hormones to enter cells. For example, dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and uses SLCO2B1 to get into cells. Similarly, statins use SLCO2B1 to enter cells as well. Previous research has suggested an association between statin use and ...
2015-05-07
Crigler-Najjar syndrome is a rare autosomal recessive disorder caused by mutations in the UGT1A1 gene, which result in the toxic accumulation of bilirubin, a substance made by the liver in the body. Indeed, when the UDP-glucuronosyltransferase 1 isotype A1 (UGT1A1), the enzyme responsible for removing bilirubin, doesn't work, the substance accumulates, causing a severe and chronic jaundice, and becoming toxic for the brain and leading to lethality.
Gene therapy has allowed the restoration of an equivalent level of bilirubin to those found in healthy animals
Federico ...
2015-05-07
This news release is available in French. Metabolic complications of obesity and overweight, such as type 2 diabetes, are an important challenge to public health. Teams led by Nicolas Venteclef, Inserm Research Fellow (Cordeliers Research Centre, Inserm/Pierre and Marie Curie University Joint Research Unit 1138, Paris, France) and Irina Udalova (Kennedy Institute of Rheumatology, University of Oxford, UK) in collaboration with several teams, have succeeded in elucidating part of the mechanisms involved in the development of these metabolic complications associated with ...
2015-05-07
Obesity and depression -- not only lack of sleep -- are underlying causes for regular drowsiness, according to Penn State College of Medicine researchers. They say these findings could lead to more personalized sleep medicine for those with excessive daytime sleepiness (EDS).
As much as 30 percent of the general population experiences EDS -- daytime drowsiness or sleepiness occurring throughout the day that can include irresistible sleep attacks. Feeling overly tired during the day can reduce job productivity and increase errors and absenteeism and may lead to more serious ...
2015-05-07
A new, noninvasive nuclear medicine test can be used to determine whether aromatase inhibitor treatment will be effective for specific cancer patients, according to a recent study reported in The Journal of Nuclear Medicine. The research shows that a PET scan with the ligand C-11-vorozole reliably detects aromatase in all body organs - demonstrating the value of its future use to pre-determine the effectiveness of the treatment for breast, ovarian, endometrial and lung cancer patients, potentially reducing unnecessary treatment costs and adverse effects.
Aromatase inhibitors ...
2015-05-07
CHICAGO (May 7, 2015): Patients undergoing colorectal operations who participated in an enhanced recovery program left the hospital sooner and had significantly lower hospital costs than patients who had the traditional approach to their care, according to a new study, which also found further postoperative improvements after adding an infection prevention protocol. The study is published online as an "article in press" on the Journal of the American College of Surgeons website in advance of print publication later this year.
"Enhanced recovery after surgery" is a multicomponent ...
2015-05-07
Schizophrenia affects millions of people worldwide but the cause of its wide-ranging symptoms remains largely unknown.
At Brandeis University, researchers believe they have discovered an abnormality in the schizophrenic brain that could be responsible for many of the disease's symptoms and could provide a drug target for therapeutic treatments.
Led by John Lisman, the Zalman Abraham Kekst Chair in Neuroscience and professor of biology, the research team published their findings in a recent issue of the Journal of Biological Psychiatry. The paper was co-authored by ...
2015-05-07
Traditionally, patients with endometrial cancer -- cancer of the womb lining -- have their disease risk classified using a combination of clinical and tissue characteristics, including their age and the growth and invasion of their tumour.
Around 15-20% of patients have high-risk disease, but it is unclear what the best treatment approach is for these patients. Now Manchester researchers have investigated genetic alterations in high-risk endometrial cancer, to see if they could be used to create tumour subtypes.
Professor Richard Edmondson, Professor of Gynaecological ...
2015-05-07
Amsterdam, May 7, 2015 -- Elsevier journal Maturitas today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) covering non-hormonal management of menopausal vasomotor symptoms.
Hot flashes are a common menopausal symptom. They tend to intensify during the perimenopause and usually subside within 5 years after the final menstrual period. However in some women frequent hot flashes are a long term problem and may last for more than 7 years. While estrogen-based menopausal hormone therapy is the most effective treatment ...
LAST 30 PRESS RELEASES:
[Press-News.org] Cancer drugs approved quickly but not to patient's benefit: York University researcher
Dr. Joel Lexchin cites earlier research reviewing solid cancer drugs within 10 years of EMA approval to point out that these drugs improved survival by just over a month
